Emergent BioSolutions director files Form 3

Emergent BioSolutions Inc. director John D. Fowler Jr filed an initial ownership report on Form 3 showing he directly beneficially owns no shares of the company’s common stock as of the reported date.

Accepted by SEC EDGAR 03/05/2026 - 09:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Emergent BioSolutions Inc. director John D. Fowler Jr filed an initial ownership report on Form 3 showing he directly beneficially owns no shares of the company’s common stock as of the reported date. The filing does not report any buy or sell transactions, only a zero balance.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider FOWLER JOHN D JR

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 0 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Emergent BioSolutions (EBS) director John D. Fowler Jr’s Form 3 show?

The Form 3 shows that director John D. Fowler Jr reports owning no shares of Emergent BioSolutions common stock directly. It is an initial ownership statement and does not include any purchase or sale activity.

Did John D. Fowler Jr buy or sell Emergent BioSolutions (EBS) shares in this Form 3?

This Form 3 does not report any purchases or sales of Emergent BioSolutions stock. It only states that the director’s direct holdings of common stock are zero following the reported position.

How many Emergent BioSolutions (EBS) shares does John D. Fowler Jr report owning?

John D. Fowler Jr reports owning 0 shares of Emergent BioSolutions common stock directly after the reported position. This indicates no direct beneficial ownership of common stock in this filing.

What type of security is covered in John D. Fowler Jr’s Emergent BioSolutions (EBS) Form 3?

The Form 3 covers common stock of Emergent BioSolutions Inc. The director reports a direct beneficial holding of zero shares of this common stock in the filing.

Is John D. Fowler Jr identified as a director of Emergent BioSolutions (EBS) in this Form 3?

Yes. The Form 3 identifies John D. Fowler Jr as a director of Emergent BioSolutions Inc. It discloses his initial direct beneficial ownership position in the company’s common stock as zero shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

FOWLER JOHN D JR

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.